[
  {
    "ts": null,
    "headline": "Why Regeneron (REGN) Shares Are Falling Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare forum.",
    "url": "https://finnhub.io/api/news?id=cf0d9fc26af0f13ac2013817cec42b55aeb67de211a308fa716d7157a2327a9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758833462,
      "headline": "Why Regeneron (REGN) Shares Are Falling Today",
      "id": 136888430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare forum.",
      "url": "https://finnhub.io/api/news?id=cf0d9fc26af0f13ac2013817cec42b55aeb67de211a308fa716d7157a2327a9e"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=70475e70b10a6dc6b9e7f1daa9da27c0e60b21fd86bc1472da45fc5a15e8769d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758818760,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 136928052,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=70475e70b10a6dc6b9e7f1daa9da27c0e60b21fd86bc1472da45fc5a15e8769d"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst",
    "summary": "Immuneering Corporation upgraded to Strong Buy after positive phase 2a data in pancreatic cancer. Click here to find out why IMRX stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=a9b61f5b9b7c05e5f8d9e6c0fcaaf26a7dc5d01cecfbffa23fe5f46949cad10f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758809987,
      "headline": "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst",
      "id": 136885293,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2234628683/image_2234628683.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Immuneering Corporation upgraded to Strong Buy after positive phase 2a data in pancreatic cancer. Click here to find out why IMRX stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=a9b61f5b9b7c05e5f8d9e6c0fcaaf26a7dc5d01cecfbffa23fe5f46949cad10f"
    }
  },
  {
    "ts": null,
    "headline": "1 Safe-and-Steady Stock on Our Watchlist and 2 We Question",
    "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
    "url": "https://finnhub.io/api/news?id=2256a2fc363e588de017a1ee4330148b0a4b45547a7be744210cd9315e0013d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758775050,
      "headline": "1 Safe-and-Steady Stock on Our Watchlist and 2 We Question",
      "id": 136883349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
      "url": "https://finnhub.io/api/news?id=2256a2fc363e588de017a1ee4330148b0a4b45547a7be744210cd9315e0013d9"
    }
  }
]